[go: up one dir, main page]

CH546760A - Beta-pyridylcarbinol nicotinoylglycinate - with vasodilatory and hypolipaemic activity, prepn. from nicotinuric acid and nicotinyl alcohol - Google Patents

Beta-pyridylcarbinol nicotinoylglycinate - with vasodilatory and hypolipaemic activity, prepn. from nicotinuric acid and nicotinyl alcohol

Info

Publication number
CH546760A
CH546760A CH546760DA CH546760A CH 546760 A CH546760 A CH 546760A CH 546760D A CH546760D A CH 546760DA CH 546760 A CH546760 A CH 546760A
Authority
CH
Switzerland
Prior art keywords
nicotinoylglycinate
pyridylcarbinol
beta
nicotinuric acid
vasodilatory
Prior art date
Application number
Other languages
French (fr)
Original Assignee
Soc D Etudes Prod Chimique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soc D Etudes Prod Chimique filed Critical Soc D Etudes Prod Chimique
Publication of CH546760A publication Critical patent/CH546760A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The novel cpd., beta-pyridylcarbinol nicotinoylglycinate (I) is prepd. by reaction of nicotinuric acid and nicotinyl alcohol in the presence of H2SO4 at 70-150 degrees C. (I) reduces capillary permeability, and has hypolipaemic and hypocholesterolaemic effects.

Description

  

  
 



   L'invention concerne la préparation du nouveau composé nicotinoyl glycinate de   ss-pyridyl    carbinol répondant à la formule suivante:
EMI1.1     

 Ce corps dont la formule brute est   Cs4Hs303N3    a un poids moléculaire de 271,2. L'invention concerne donc le procédé de préparation de ce corps selon lequel on fait réagir l'acide nicotinurique sur l'alcool nicotinique en présence d'acide sulfurique à des températures comprises entre 70 et   1500C.   



   En effet, ce composé présente une action thérapeutique favorable dans le domaine vasculaire et, en particulier, présente une bonne action vasodilatatrice périphérique associée à des actions hypolipémiante et   hypocholestérolémiante.   



   La préparation du corps par le procédé selon l'invention sera mieux comprise grâce à la description des exemples qui suivent.



   Exemple I
 Dans un réacteur de 10 litres équipé de moyens d'agitation, on verse 2,5 I d'acide sulfurique concentré et on ajoute ensuite sous agitation 2,5 kg d'acide nicotinurique (la quantité d'acide nicotinurique correspond à un excès d'environ   30%    par rapport à l'alcool nicotinique qui sera ajouté par la suite). La température s'élève jusqu'à   80-90oC    puis s'abaisse à   65-750C.   



  On ajoute à ce moment-là, très rapidement et sous agitation, tout en refroidissant 1 kg d'alcool nicotinique (correspondant à   0,92    1). On maintient l'agitation pendant 15 mn, à une température de   60-70OC    puis on verse la solution obtenue dans un réacteur contenant 34 I d'eau et 7,8 kg de bicarbonate de sodium. On contrôle le pH qui doit être aux environs de 7-7,5 et, si nécessaire. on l'ajuste à cette valeur puis la solution est extraite à la température de   25-30cC,    deux fois avec du chlorure de méthylène (la première fois par 5 1, la seconde fois par   2,51).    La solution d'extraction est ensuite lavée avec une solution soufrée de chlorure de sodium puis séchée par du sulfate de sodium et décolorée au noir de carbone.

  Après filtration et lavage au chlorure de méthylène on concentre la solution à sec sous pression réduite à   50-600C.    On obtient ainsi 1,2 kg d'extrait sec qui est redissous dans l'acétate d'éthyle à ébullition. On laisse cette solution refroidir tout doucement jusqu'à 0/ +   50C    sous agitation lente pendant au moins 3 heures, à cette même température.



   Le nicotinoyl glycinate de   5-pyridyl    carbinol précipite et on le sépare par filtration et on le lave. On obtient ainsi 1 kg de produit c'est-à-dire environ   406suc    en poids de rendement par rapport au matériau de départ. L'analyse montre que le produit obtenu correspond bien à la formule   C14H13O3N3.   



   En ce qui concerne maintenant l'obtention de l'acide nicotinurique, ce composé peut être préparé en faisant réagir dans un réacteur de 40 I parfaitement sec, 2,2 kg de chlorhydrate d'éthyle glycinate et 2,8 kg de chlorhydrate de chlorure de nicotinoyle en suspension dans 16 I de dichloréthane sec. Cette suspension est chauffée sous agitation jusqu'à   60-700C    et l'acide chlorhydrique se dégage. Lorsque tout l'acide chlorhydrique a été évacué le mélange réactionnel est refroidi à 20    25l C et extrait par 151 d'eau. La solution extraite est traitée    par une lessive de potasse à une température n'excédant pas   25iC    jusqu'à ce que   l'on    obtienne un pH de 12-12,5.

  On décolore ensuite cette solution au noir de carbone, on la filtre puis on lui ajoute sous agitation de l'acide chlorhydrique pour amener le pH à   3/+0,2.    On obtient ainsi une suspension d'acide nicotinurique qui est agitée au moins   7    heures à la température ambiante.



   On sépare ensuite ce précipité, on le sèche soigneusement et on recueille   2,5    kg d'acide ce qui représente environ un rende   ment de 88 6su en poids par rapport à l'éthyle glycinate de    départ.



   Exemple 2
 En utilisant le même appareillage que dans l'exemple 1 on réalise cette synthèse cette fois en présence d'un excès d'alcool nicotinique. On place dans le réacteur 1,8 kg d'acide nicotinurique et   2,9    kg d'alcool nicotinique (ce qui correspond à un excès d'environ   1006suc    par rapport à l'acide nicotinurique) puis sous agitation. 1 kg d'acide sulfurique. La suspension ainsi obtenue est portée à   130OC    pendant 8 heures. sous agitation.



  puis l'excès d'alcool nicotinique est évacué par distillation et on ajoute lentement   31    d'eau. On ajuste le pH du mélange réactionnel à 7 par addition d'une solution d'ammoniaque. A ce pH apparaît un précipité correspondant à la portion d'acide nicotinurique n'ayant pas réagi: on le sépare et il peut être réutilisé dans une synthèse ultérieure. La solution obtenue par ailleurs est traitée par une solution de chlorure de sodium saturée puis extraite au chloroforme. décolorée et recristallisée comme dans l'exemple 1. Le rendement est de   25'oc    par rapport à l'acide nicotinurique ayant réagi.



   TOXICITE
 Le nicotinoyl glycinate de   5-pyridyl    carbinol présente une faible toxicité. Par voie intrapéritonéale sur la souris. la DL 50 est de 3.2   g/kg    tandis qu'elle est de 5   g kg    per os. La toxicité subaiguë déterminée sur les rats à des doses de 0.1 à 0,2 de la
DL 50 n'a provoqué aucun décès ni révélé aucun trouble.



   PHARMACOLOGIE
 L'action dans le domaine de la vasodilatation périphérique a été prouvée par l'expérience de l'oreille perfusée de lapin où cette action a été mise en évidence à partir de la dose de 0,5 mg/ml. L'action   hypolipémiante    et   hypocholestérolémiante    a été prouvée sur des lapins hypercholesterolémiés, traités par 0,3   g/kg    de nicotinoyl glycinate de   P-pyridyl    carbinol. Les résultats de dosages du cholesterol total. du cholestérol   estéri-    fiée, des triglycérides et des lipides totaux sont reportés dans le tableau ci-dessous dans lequel:
A correspond aux valeurs moyennes sur 6 lapins ayant reçu un régime hypercholestérolémiant.

 

  B correspond aux valeurs moyennes pour un autre lot de 6 lapins n'ayant reçu ni régime hypercholestérolémiant ni traitement,
C correspond aux valeurs moyennes obtenues sur un lot de 6 lapins hypercholestérolémiés puis traités par le produit de l'invention, comme indiqué ci-dessus.



   Total: Cholestérol   Triglycéndes    Lipides
 Cholestérol estérifié totaux
 A 8,7 6.60 13.70   22,72   
 B 0,56 0,50   1,52    3,60
 C 5,36   3.77      A,06      14,53   
 Enfin, ce composé abaisse la perméabilité capillaire ainsi qu'on peut le vérifier par le test du bleu trypan effectué sur le  lapin: les doses efficaces sont comprises entre 5 et 50 mg/kg en administration per os.



   POSOLOGIE
 Ce composé peut être utilisé dans des médicaments destinés au traitement des artérioscléroses cérébrales et des diverses formes d'artériopathies. Pour l'administration en thérapeutique humaine, les doses utilisables sont comprises entre 0,1 et 3 g par jour. La durée du traitement est de 20 jours. Du point de vue pratique les doses les plus couramment utilisées se situent entre 0,5 et 1,5 g par jour. A titre d'exemple de forme d'administration préférée on peut utiliser des gélules qui contiennent de 0,10 à 0,25 g de principe actif associé à un excipient approprié comme par exemple du lactose. Ce composé peut également être administré par injection à des doses quotidiennes de 0,1 à 1 g, administrées en une seule injection, la durée du traitement pourrait être de 10 jours. 

  Dans ce cas le médicament peut être présenté sous la forme d'un extrait sec contenu dans une ampoule et d'une solution isotonique destinée à préparer extemporanément la dose avant l'injection. 



  
 



   The invention relates to the preparation of the novel ss-pyridyl carbinol nicotinoyl glycinate compound corresponding to the following formula:
EMI1.1

 This body, the molecular formula of which is Cs4Hs303N3, has a molecular weight of 271.2. The invention therefore relates to the process for preparing this body according to which nicotinuric acid is reacted with nicotinic alcohol in the presence of sulfuric acid at temperatures between 70 and 1500C.



   Indeed, this compound exhibits a favorable therapeutic action in the vascular field and, in particular, exhibits a good peripheral vasodilator action associated with lipid-lowering and hypocholesterolemic actions.



   The preparation of the body by the process according to the invention will be better understood from the description of the examples which follow.



   Example I
 2.5 L of concentrated sulfuric acid are poured into a 10-liter reactor equipped with stirring means and then 2.5 kg of nicotinuric acid are added with stirring (the amount of nicotinuric acid corresponds to an excess of 'about 30% compared to the nicotinic alcohol which will be added later). The temperature rises to 80-90oC and then drops to 65-750C.



  At this point, very quickly and with stirring, while cooling 1 kg of nicotinic alcohol (corresponding to 0.92 1) is added. Stirring is maintained for 15 min, at a temperature of 60-70OC then the solution obtained is poured into a reactor containing 34 l of water and 7.8 kg of sodium bicarbonate. The pH is checked which should be around 7-7.5 and, if necessary. it is adjusted to this value and then the solution is extracted at a temperature of 25-30 ° C., twice with methylene chloride (the first time by 5 l, the second time by 2.51). The extraction solution is then washed with a sulfur-containing solution of sodium chloride then dried with sodium sulphate and decolorized with carbon black.

  After filtration and washing with methylene chloride, the solution is concentrated to dryness under reduced pressure at 50-600C. 1.2 kg of dry extract is thus obtained, which is redissolved in ethyl acetate at the boiling point. This solution is left to cool very slowly to 0 / + 50C with slow stirring for at least 3 hours, at this same temperature.



   5-Pyridyl carbinol nicotinoyl glycinate precipitates and is filtered off and washed. In this way 1 kg of product is obtained, that is to say approximately 40% by weight of yield relative to the starting material. Analysis shows that the product obtained corresponds to the formula C14H13O3N3.



   As regards now the obtaining of nicotinuric acid, this compound can be prepared by reacting in a perfectly dry 40 I reactor, 2.2 kg of ethyl glycinate hydrochloride and 2.8 kg of chloride hydrochloride. of nicotinoyl suspended in 16 l of dry dichloroethane. This suspension is heated with stirring up to 60-700C and hydrochloric acid is evolved. When all the hydrochloric acid has been removed, the reaction mixture is cooled to 20 251 C and extracted with water. The extracted solution is treated with a potash lye at a temperature not exceeding 25 ° C until a pH of 12-12.5 is obtained.

  This solution is then decolorized with carbon black, filtered and then hydrochloric acid is added to it with stirring to bring the pH to 3 / + 0.2. A suspension of nicotinuric acid is thus obtained which is stirred for at least 7 hours at room temperature.



   This precipitate is then separated, dried carefully and 2.5 kg of acid are collected, which represents a yield of approximately 88% by weight relative to the starting ethyl glycinate.



   Example 2
 Using the same apparatus as in Example 1, this synthesis is carried out this time in the presence of an excess of nicotinic alcohol. 1.8 kg of nicotinuric acid and 2.9 kg of nicotinic alcohol (which corresponds to an excess of approximately 1006suc relative to the nicotinuric acid) are placed in the reactor, followed by stirring. 1 kg of sulfuric acid. The suspension thus obtained is brought to 130OC for 8 hours. under agitation.



  then the excess nicotinic alcohol is removed by distillation and 31 water is slowly added. The pH of the reaction mixture is adjusted to 7 by the addition of an ammonia solution. At this pH, a precipitate appears corresponding to the portion of unreacted nicotinuric acid: it is separated and it can be reused in a subsequent synthesis. The solution obtained, moreover, is treated with a saturated sodium chloride solution and then extracted with chloroform. decolorized and recrystallized as in Example 1. The yield is 25 ° C. based on the reacted nicotinuric acid.



   TOXICITY
 5-Pyridyl carbinol nicotinoyl glycinate has low toxicity. By the intraperitoneal route in mice. the LD 50 is 3.2 g / kg while it is 5 g kg per os. Subacute toxicity determined in rats at doses of 0.1 to 0.2 of the
LD 50 did not cause any death or reveal any disorder.



   PHARMACOLOGY
 The action in the field of peripheral vasodilation has been proved by the experiment of the perfused rabbit ear where this action has been demonstrated from the dose of 0.5 mg / ml. The lipid-lowering and cholesterol-lowering action has been proven in hypercholesterolemic rabbits treated with 0.3 g / kg of P-pyridyl carbinol nicotinoyl glycinate. The results of total cholesterol assays. esterified cholesterol, triglycerides and total lipids are shown in the table below in which:
A corresponds to the mean values on 6 rabbits having received a hypercholesterolemic diet.

 

  B corresponds to the mean values for another batch of 6 rabbits that received neither hypercholesterolemic diet nor treatment,
C corresponds to the mean values obtained on a batch of 6 hypercholesterolemic rabbits then treated with the product of the invention, as indicated above.



   Total: Cholesterol Triglycéndes Lipids
 Total esterified cholesterol
 A 8.7 6.60 13.70 22.72
 B 0.56 0.50 1.52 3.60
 C 5.36 3.77 A, 06 14.53
 Finally, this compound lowers capillary permeability as can be verified by the trypan blue test carried out on the rabbit: the effective doses are between 5 and 50 mg / kg when administered orally.



   DOSAGE
 This compound can be used in medicaments intended for the treatment of cerebral arteriosclerosis and various forms of arterial disease. For administration in human therapy, the doses that can be used are between 0.1 and 3 g per day. The duration of treatment is 20 days. From a practical point of view the most commonly used doses are between 0.5 and 1.5 g per day. As an example of a preferred form of administration, it is possible to use gelatin capsules which contain from 0.10 to 0.25 g of active principle combined with an appropriate excipient such as, for example, lactose. This compound can also be administered by injection in daily doses of 0.1 to 1 g, administered as a single injection, the duration of treatment could be 10 days.

  In this case, the medicament can be presented in the form of a dry extract contained in an ampoule and of an isotonic solution intended to prepare the dose extemporaneously before the injection.

 

Claims (1)

REVENDICATION CLAIM Procédé de préparation du nicotinoyl glycinate de ss-pyridyl carbinol, consistant à faire réagir l'acide nicotinurique sur l'alcool nicotinique en présence d'acide sulfurique à des températures comprises entre 70 et 1500C. Process for the preparation of ss-pyridyl carbinol nicotinoyl glycinate, consisting of reacting nicotinuric acid with nicotinic alcohol in the presence of sulfuric acid at temperatures between 70 and 1500C.
CH546760D 1972-01-05 1972-01-05 Beta-pyridylcarbinol nicotinoylglycinate - with vasodilatory and hypolipaemic activity, prepn. from nicotinuric acid and nicotinyl alcohol CH546760A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH10572 1972-01-05

Publications (1)

Publication Number Publication Date
CH546760A true CH546760A (en) 1974-03-15

Family

ID=4179379

Family Applications (1)

Application Number Title Priority Date Filing Date
CH546760D CH546760A (en) 1972-01-05 1972-01-05 Beta-pyridylcarbinol nicotinoylglycinate - with vasodilatory and hypolipaemic activity, prepn. from nicotinuric acid and nicotinyl alcohol

Country Status (1)

Country Link
CH (1) CH546760A (en)

Similar Documents

Publication Publication Date Title
CA2150162C (en) New n-pyridyl carboxamides and derivatives thereof, preparation processes thereof and pharmaceutical compositions containing thereof
EP0318377A2 (en) Enantiomeric derivatives of amino acids, process for their preparation and their pharmaceutical applications
BE834794A (en) 3-TRIHYDROXYGERMANO-PROPIONIC ACID
FR2511366A1 (en) NOVEL DERIVATIVES OF PYRIDAZINE, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS ACTIVE ON THE CENTRAL NERVOUS SYSTEM CONTAINING THE SAME
CA1196650A (en) 4-aminoethoxy-5-isopropyl-2-methyl phenyl derivatives; process for preparing the same and their use as therapeutic agents
EP0125195A1 (en) 4'-Flavonecarboxylic acids, process for their preparation and their therapeutical use
CA1312333C (en) Strontium salt, its preparation process and the pharmaceutical compositions containing it
EP0606175B1 (en) 2-Cyano-3-hydroxypropenamide derivatives, process for their preparation, their use as medicaments and pharmaceutical compositions containing them
EP0301936B1 (en) Piperidine derivatives, their preparation and their therapeutical use
CH546760A (en) Beta-pyridylcarbinol nicotinoylglycinate - with vasodilatory and hypolipaemic activity, prepn. from nicotinuric acid and nicotinyl alcohol
FR2610932A1 (en) NOVEL PIPERAZINECARBOXYLIC ACID, ITS PREPARATION AND ITS USE AS A MEDICINAL PRODUCT
EP0487423A1 (en) Benzoselenazolinone derivatives, their preparation and pharmaceutical compositions containing them
CH615673A5 (en)
FR2742151A1 (en) USE OF MONO OR DICETONIC BICYCLE DERIVATIVES, NOVEL COMPOUNDS OBTAINED AND THEIR THERAPEUTIC USE
FR2701261A1 (en) New glucuronide compounds of diosmetin, process for their preparation and the pharmaceutical compositions containing them
EP0082040B1 (en) 3,7a-diazacyclohepta(j,k)fluorene derivatives, their preparation and therapeutical use
CH658786A5 (en) DRUGS THAT CONTAIN ALPHA- (N-PYRROLYL) -ACIDS OR THEIR SALTS OR ESTERS.
EP1007522B1 (en) 2- 4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]piperazin-1-yl -5-fluoropyrimidine, its preparation and therapeutic use
CA1068270A (en) 2,4-diamino-5-bromo-6-chloro pyrimidines, process of making them and pharmaceutical applications
CH395140A (en) Process for the preparation of new acetanilide derivatives
FR2569562A1 (en) THERAPEUTIC COMPOSITIONS BASED ON NOVEL AMINOMETHYL-6 FURO- (3,4-C) -PYRIDINE DERIVATIVES
CH411820A (en) Process for the preparation of novel heparin compounds which can be used, in particular, for the treatment of disorders of blood coagulability
FR2555899A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE GLYCYRRHETINIC ACID DERIVATIVE AND AT LEAST ONE XANTHINE DERIVATIVE
CH259253A (en) Process for preparing acetylcholine oleate.
FR2480602A1 (en) HEXAHYDRO-PYRIMIDO (1,2-A) AZEPINES 3-SUBSTITUTED AS DRUGS

Legal Events

Date Code Title Description
PL Patent ceased